%0 Journal Article %J PROTEOMICS %D 2018 %T Estimating the Reliability of Low-Abundant Signals and Limited Replicate Measurements through MS2 Peak Area in SWATH %A Franck Limonier %E Willems, Sander %E Maarten Dhaenens %Y Geneviève Waeterloos %Y Myriam Sneyers %Y Deforce, Dieter %K MS2 peak area %X

Sequential windows acquisition of all theoretical fragment ions mass spectrometry (SWATH-MS) provides large-scale protein quantification with high accuracy and selectivity. Nevertheless, reliable quantification of low-abundant signals in complex samples remains challenging, as recently illustrated in a multicenter benchmark study of different label-free software tools. Here, the SWATH Replicates Analysis 2.0 template from Sciex is used to highlight that the relationship between the MS2 peak area and the variability can be described by a function. This functional relationship appears to be largely insensitive to variation in samples or acquisition conditions, suggesting a device-intrinsic property. By using a power regression, it is shown that the MS2 peak area can be used to predict the quantification repeatability without relying on replicate injections, thus contributing to high-throughput confident quantification of low-abundant signals with SWATH-MS.

%B PROTEOMICS %8 Nov-02-2018 %G eng %R 10.1002/pmic.201800186 %0 Journal Article %J J Proteomics %D 2017 %T An application of mass spectrometry for quality control of biologicals: Highly sensitive profiling of plasma residuals in human plasma-derived immunoglobulin. %A Franck Limonier %A Van Steendam, Katleen %A Geneviève Waeterloos %A Koen Brusselmans %A Myriam Sneyers %A Deforce, Dieter %X

Thromboembolic events (TEE) associated to trace amounts of plasmatic activated coagulation factor XI (FXIa) in administrated immunoglobulin (Ig) have recently raised concerns and hence there is a need for highly sensitive profiling of residual plasma source proteins. This study aims to consider LC-ESI-QTOF data-dependent acquisition in combination with sample fractionation for this purpose. Sample fractionation proved mandatory to enable identification of plasma residuals. Two approaches were compared: Ig depletion with protein G - protein A affinity chromatography and low-abundant protein enrichment with a combinatorial peptide ligand library (ProteoMiner™, Bio-Rad). The latter allowed a higher number of identifications. Highly sensitive detection of prothrombotic FXIa was assessed with confident identification of a 1ng/mg spike. Moreover, different residuals compositions were profiled for various commercial Ig products. Using a quantitative label free analysis, a TEE-positive Ig batch was distinguished from other regular Ig products, with increased levels of FXIa but also other unique proteins. This could have prevented the recently observed TEE problems with Ig. The method is a convenient tool to better characterize Ig products after any plasma pool or manufacture process change, gaining insights in the product quality profile without any prior information required.

BIOLOGICAL SIGNIFICANCE: This study characterized residual plasma proteins in Ig products, using bottom-up LC-MS/MS with conventional data-dependent acquisition, preceded by sample fractionation. Without any prior information or target-specific development, >30 proteins were identified in a commercial Ig product. Quality control relevance was demonstrated with the identification of FXIa spiked at 1ng/mg in Ig, which is below the minimal thrombotic dose of 3ng/mg observed in an in vivo model. Relative label-free quantitation highlighted significant differences in normalized abundances of residual proteins between Ig products. A TEE-positive batch was distinguished by unique profile of residual proteins, including FXIa but also various blood stream-regulator proteins (fibrinogen, angiotensinogen, antithrombin-III, complement component C8, …). Those results emphasize that MS screening is a relevant first-line test to prevent any undesired concentration of plasma impurities after a plasma pool or manufacturing process change.

%B J Proteomics %V 152 %P 312-320 %8 2017 Jan 30 %G eng %1 http://www.ncbi.nlm.nih.gov/pubmed/27894965?dopt=Abstract %R 10.1016/j.jprot.2016.11.007 %0 Journal Article %J Journal of Business Continuity & Emergency Planning %D 2017 %T Health crisis due to infectious and communicable diseases: European preparedness and response tools in an international context %A Patrick Mahy %A Jean Marc Collard %A Jean-Luc Gala %A Philippe Herman %A Dirk De Groof %A Sophie Quoilin %A Myriam Sneyers %K communicable %K crisis %K Diseases %K health %K Infectious %K preparedness %X

The combination of changes in eating habits, ways of living, globalisation, extensive travelling and the migration of millions of people around the world may be contributing to increased health risks. Certainly, health crises today are proving highly complex. More and more people are travelling and may carry with them unexpected virus vectors such as mosquitoes. Preparedness is challenging and there is a need for action plans to safeguard the growing at-risk population. Health crises can potentially affect a large proportion of the population and may lead to a significant increase in mortality or to an abnormally high death rate. This should be integrated into the general concept of national and international surveillance in order to provide a prepared response in the event of crisis. This paper provides an inventory of the relevant laws, guidelines and tools in Europe (and to a lesser degree, beyond), and proposes answers to the health crisis problems associated with infectious and communicable diseases. In crisis management, communication is an important factor to consider. This paper can serve as a tool for people involved in crisis preparedness.

%B Journal of Business Continuity & Emergency Planning %V 10 %8 2017-06-01 %G eng %N 4 %& 353 %R http://www.ingentaconnect.com/content/hsp/jbcep/2017/00000010/00000004/art00007 %0 Report %D 2016 %T Goal 4: Develop and implement new technologies and methods to improve WIV-ISP's responsiveness to public health threats %A Myriam Sneyers %A Nancy Roosens %A Sigrid C.J. De Keersmaecker %E Johan Peeters %K AS %K Case %K Development %K health %K implement %K improve %K method %K methods %K public %K public health %K Public-health %K report %K Salmonella %K study %K Subtyping %K technology %K WIV-ISP %I WIV-ISP %C Brussels, Belgium %P 114 %8 30/6/2016 %@ D/2015/2505/03 %G eng %9 Scientific Report 2014-2015 %1 5786 %& 17 %0 Generic %D 2014 %T Mass spectrometry-based proteomics for the quality control of intravenous immunoglobulin: Detection of possible thrombogenic impurities %A Franck Limonier %A Van Steendam,K. %A Geneviève Waeterloos %A Myriam Sneyers %A Deforce,D. %E Human Proteome Organization %K Biology %K Control %K detection %K disease %K Human %K Immunoglobulin %K Mass %K Proteomics %K Quality %K Quality Control %K world %B 13th Human ProteomeOrgonization world congres: The proteome quest to understand biology and disease %8 5/10/2014 %G eng %N Human proteome organization %1 38804 %2 5-8/10/2014 %0 Journal Article %J Eur Food Res Technol %D 2012 %T Four new SYBR®Green qPCR screening methods for the detection of Roundup Ready(r), LibertyLink(r), and CryIAb traits in genetically modified products362 %A E. Barbau-Piednoir %A A. Lievens %A Els Vandermassen %A G.E. Mbongolo-Mbella %A Amaya Leunda %A Nancy Roosens %A Myriam Sneyers %A Marc Van den Bulcke %K a %K ALL %K an %K analysi %K analysis %K application %K AS %K at %K Bacillus %K Bacillus thuringiensis %K Cost %K COSTS %K CoSYPS %K detection %K Efficiency %K Feed/food analysis %K genetically %K Genetically modified %K Genetically modified organism %K Genetically modified organisms %K global %K GM %K GMO %K GMO detection %K Herbicide resistance %K identification %K Insect resistance %K IS %K LEVEL %K levels %K method %K methods %K PCR %K present %K PRODUCTS %K qPCR %K Quantitative real-time PCR %K r %K RANGE %K result %K results %K Sample %K Samples %K SCREENING %K Screening method %K SENSITIVITY %K specific %K specificity %K SYBR(r)Green %K SYBRgreen %K Target %K Targets %K Test %K Traits %X SYBR(r)Green qPCR methods for the detection of the Roundup Ready (r) "CP4-EPSPS", LibertyLink (r) "PAT" and "BAR" and the Bacillus thuringiensis "CryIAb" traits as present in genetically modified organisms (GMO) were developed. Their specificity, sensitivity, and PCR method efficiency were determined. All methods are specific and generate amplicons of 108, 73, 109, and 69 bp, respectively, for "CP4-EPSPS", "CryIAb", "PAT" and "BAR" targets. They perform well at low target levels and can detect down to 5 copies of their respective targets extracted from a sample. The PCR efficiency of the methods ranges between 91 and 109%. Due to their trait-specific nature, these methods allow an efficient screening between the different GMO. In this way, the number of possible GMO candidates present in a sample can be reduced what results in lower global costs due to limiting of further the number of analytical identification steps. The application of these methods in CoSYPS GMO analysis is illustrated using two GEMMA proficiency test samples and a reference material from the GM rapeseed event RF3. This set of SYBR(r)Green qPCR trait-specific methods represents a very interesting novel set of GMO analysis methods allowing cost-effective identification of GM materials in products. %B Eur Food Res Technol %V 234 %P 13 - 23 %8 1/1/2012 %@ 1438-2377 %G eng %N 1 %1 38507 %& 13 %R DOI: 10.1007/s00217-011-1605-7 %0 Journal Article %J Eur.Food Res.Technol. %D 2011 %T SYBR®Green qPCR methods for detection of endogenous reference genes in commodity crops: a step ahead in combinatory screening of Genetically Modified Crops in food and feed products %A G.E. Mbongolo-Mbella %A A. Lievens %A E. Barbau-Piednoir %A Myriam Sneyers %A Amaya Leunda %A Nancy Roosens %A Marc Van den Bulcke %K an %K approach %K approaches %K at %K Biomedical and Life Sciences %K criteria %K crops %K detection %K Development %K Efficiency %K EU %K European %K European Union %K feed %K food %K gene %K Genes %K Genetically modified %K Genetically modified crop %K genetically modified crops %K Genetically modified organism %K Genetically modified organisms %K GMO %K IS %K Laboratories %K maize %K method %K methods %K Network %K Oilseed rape %K Order %K PCR %K performance %K polymerase chain reaction %K PRODUCTS %K qPCR %K SCREENING %K Soybean %K Strategies %K Strategy %K sugar %X Identification of crops present in food and/or feed matrices represents an important step in the screening strategies targeting genetically modified organisms (GMO). Soybean, maize, oilseed rape, rice, cotton, sugar beet and potato are to date the most important sources of genetically modified materials imported in the European Union (EU). In order to allow detection of their presence in an integrated screening approach, a set of SYBR-«Green real-time polymerase chain reaction (qPCR) methods has been developed which can be used under the same assay conditions and at similar efficiency for each of the abovementioned crops. Each qPCR method is shown to meet the performance criteria (i.e. specificity, limit of detection and PCR efficiency) set by the European Network of GMO Laboratories (ENGL). When combined with the equivalent qPCR methods targeting GMO elements, these crop-specific SYBR-«Green qPCR methods can aid the development of an efficient tool for determining GMO presence in food and/or feed products %B Eur.Food Res.Technol. %V 232 %P 485 - 496 %8 1/3/2011 %@ 14382377 %G eng %N 3 %1 345 %& 485 %R http://dx.doi.org/10.1007/s00217-010-1408-2 %0 Report %D 2010 %T Development of a molecular detection platform for GMO detection in food based on "combinatory qPCR" technology %A Nancy Roosens %A E. Barbau-Piednoir %A A. Lievens %A G.E. Mbongolo-Mbella %A D. Van Geel %A Els Vandermassen %A Amaya Leunda %A Sylvia Broeders %A Myriam Sneyers %A Marc Van den Bulcke %K a %K detection %K Development %K food %K GMO %K GMO detection %K Molecular %K molecular detection %K ON %K technology %I WIV-ISP; PBB %C Brussels, Belgium %P 4 %8 0/0/2010 %@ D/2010/2505/52 %G eng %1 38867 %& 127 %0 Government Document %D 2010 %T NRL-GMO: GMODetec research project (2007-2010)408 %A E. Barbau-Piednoir %A A. Lievens %A Amaya Leunda %A Nancy Roosens %A Marc Van den Bulcke %A Myriam Sneyers %A Frédéric Debode %A Jansens,E. %A Berben,G. %A Ruttink,T. %A Isabel Taverniers %A M. De Loose %K abstract %K GMO %K Project %K Research %X No abstract %B LabInfo %V 5 %P 14 - 19 %8 0/12/2010 %G eng %N December 2010 %1 38491 %& 14 %0 Report %D 2010 %T Rapport annuel du GMOLAB concernant les dossiers de validation pour l'identification des organismes génétiquement modifiés - 01/09/09 au 31/08/10 (2009-2010) %A G.E. Mbongolo-Mbella %A Sylvia Broeders %A Els Vandermassen %A D. Van Geel %A Nancy Roosens %A E. Barbau-Piednoir %A Myriam Sneyers %A Sciacqua,M. %A Anne-Marie Vanherle %K annual report %K de %K GMO detection %K GMOlab %K LE %K qPCR %K rapport %K rapport annuel %K TaqMan(r) %K VALIDATION %I WIV-ISP; PBB %C Brussels, Belgium %P 15 %8 0/0/2010 %@ D/2010/2505/51 %G eng %1 38813 %0 Report %D 2010 %T Rapport annuel du GMOLAB concernant les dossiers de validation pour la quantification des organismes génétiquement modifiés - 01/09/09 au 31/08/10 (2009-2010) %A G.E. Mbongolo-Mbella %A Sylvia Broeders %A Els Vandermassen %A D. Van Geel %A Nancy Roosens %A E. Barbau-Piednoir %A Myriam Sneyers %A Sciacqua,M. %A Anne-Marie Vanherle %K de %K GMO quantification %K GMOlab %K LE %K qPCR %K Quantification %K rapport %K rapport annuel %K VALIDATION %I WIV-ISP %C Brussels, Belgium %P 41 %8 0/0/2010 %@ D/2010/2505/50 %G eng %1 410 %0 Journal Article %J Eur.Food.Res.Technol. %D 2010 %T SYBR®Green qPCR screening methods for the presence of "35S promoter" and "NOS terminator" elements in food and feed products400 %A E. Barbau-Piednoir %A A. Lievens %A G.E. Mbongolo-Mbella %A Nancy Roosens %A Myriam Sneyers %A Amaya Leunda %A Marc Van den Bulcke %K 35S promotor %K a %K at %K Belgium %K biosafety %K Biotechnology %K Brussels %K crops %K Efficiency %K feed %K food %K food and feed analysis %K genetically %K Genetically modified %K Genetically modified crop %K genetically modified crops %K GMO detection %K health %K Institute %K LEVEL %K levels %K low level %K M %K method %K methods %K n %K NOS terminator %K PCR %K Plasmids %K PRODUCTS %K public %K public health %K Public-health %K qPCR %K recombinant %K SBB %K SCREENING %K Screening method %K Short %K specific %K SYBR(r)Green %K Target %K Targets %K Temperature %K VIRUS %X The Cauliflower Mosaic Virus "35S promotor" (p35S) and the Agrobacterium "Nopaline Synthase" terminator (tNOS) are the most represented generic recombinant elements in commercial genetically modified crops to date. A set of four new SYBR %B Eur.Food.Res.Technol. %V 230 %P 383 - 393 %8 0/0/2010 %@ 14382377 %G eng %N 3 %1 38490 %& 383 %R 10.1007/s00217-009-1170-5 %0 Journal Article %J Anal Bioanal Chem %D 2010 %T A theoretical introduction to "combinatory SYBRGreen qPCR screening", a matrix-based approach for the detection of materials derived from genetically modified plants. %A Marc Van den Bulcke %A Lievens, Antoon %A Barbau-Piednoir, Elodie %A Guillaume Mbongolo Mbella %A Nancy Roosens %A Myriam Sneyers %A Amaya Leunda %K Algorithms %K Animal Feed %K Fluorescent Dyes %K Food Analysis %K Food, Genetically Modified %K Models, Theoretical %K Organic Chemicals %K Plants, Genetically Modified %K polymerase chain reaction %X

The detection of genetically modified (GM) materials in food and feed products is a complex multi-step analytical process invoking screening, identification, and often quantification of the genetically modified organisms (GMO) present in a sample. "Combinatory qPCR SYBRGreen screening" (CoSYPS) is a matrix-based approach for determining the presence of GM plant materials in products. The CoSYPS decision-support system (DSS) interprets the analytical results of SYBRGREEN qPCR analysis based on four values: the C(t)- and T(m) values and the LOD and LOQ for each method. A theoretical explanation of the different concepts applied in CoSYPS analysis is given (GMO Universe, "Prime number tracing", matrix/combinatory approach) and documented using the RoundUp Ready soy GTS40-3-2 as an example. By applying a limited set of SYBRGREEN qPCR methods and through application of a newly developed "prime number"-based algorithm, the nature of subsets of corresponding GMO in a sample can be determined. Together, these analyses provide guidance for semi-quantitative estimation of GMO presence in a food and feed product.

%B Anal Bioanal Chem %V 396 %P 2113-23 %8 2010 Mar %G eng %N 6 %1 http://www.ncbi.nlm.nih.gov/pubmed/19960341?dopt=Abstract %R 10.1007/s00216-009-3286-7 %0 Book %B Biotechnology - Vol I: Biosafety in Biotechnoogy %D 2009 %T Biosafety in Biotechnology %A J-M Collard %A Didier Breyer %A Renckens,S. %A Myriam Sneyers %A Van Haver,E. %A Bernadette Van Vaerenbergh %A William Moens %E Eolss %K biological safety %K biosafety %K Biotechnology %K containment %K environment %K gene therapy %K GM feed %K GM food %K GMO %K hazard %K Life %K LMO %K Public Opinion %K regulation %K Risk Assessment %K risk management %K SBB %K System %K transient expression %K vaccine %B Biotechnology - Vol I: Biosafety in Biotechnoogy %7 - %I Eolss Publishers %C Oxford, UK %P - %8 0/0/2009 %@ 978-1-84826-255-3 %G eng %9 Encyclopedia of Life Support Systems (EOLSS) %1 2794 %& 1 %0 Government Document %D 2009 %T Co-Extra: Europees project over co-existentie en traceerbaarheid van GGO en niet-GGO productieketens %A Didier Breyer %A Nancy Roosens %A Berben,G. %A Isabel Taverniers %A Marc Van den Bulcke %A Myriam Sneyers %K Co-Extra %K coexistence %K de %K GMO %K IS %K production %K SBB %K SIGMEA %X Co-Extra is een Europees project dat in april 2005 van start ging en in september 2009 wordt beëindigd. Er werkenmeer dan 200 wetenschappers aan mee die verbonden zijn aan 51 multidisciplinaire onderzoeksteams en eenaantal privé-bedrijven uit 18 landen (Europa, Brazilië, Argentinië en Rusland). Het project beschikt over een totaalbudget van 22 miljoen euro, waarvan 13 miljoen wordt betaald door de Europese Commissie via een fi nancieringsregelingvoor het 6de Europese kaderprogramma voor onderzoek.De belangrijkste doelstelling van Co-Extra bestaat erin de tools te verstrekken die nodig zijn voor de implementatievan co-existentie en traceerbaarheid met als doel de co-existentie van productieketens met GGO-producten,met gangbare producten of met producten uit de biologische landbouw te garanderen. Dit geïntegreerdeproject vormt een aanvulling op twee andere Europese projecten : SIGMEA dat vooral betrekking heeft op deco-existentie op het niveau van de landbouwproductie en Transcontainer dat zich toespitst op "biocontainment". %B LabInfo %V 3 %P 22 - 23 %8 0/0/2009 %G eng %N November 2009 %1 2806 %& 22 %0 Government Document %D 2009 %T Co-Extra: Projet européen sur la coexistence et la traçabilité des filières OGM et non-OGM %A Didier Breyer %A Nancy Roosens %A Berben,G. %A Isabel Taverniers %A Marc Van den Bulcke %A Myriam Sneyers %K Co-Extra %K coexistence %K de %K Europe %K GMO %K LE %K OGM %K production %K programme %K SBB %K SIGMEA %X Co-Extra est un projet européen qui a débuté en avril 2005 et fi nira en septembre 2009. Il regroupe plus de 200scientifi ques appartenant à 51 équipes de recherche multidisciplinaires ainsi que plusieurs compagnies privées,provenant de 18 pays (Europe, Brésil, Argentine et Russie). Le projet dispose d'un budget total de 22 millionsd'euros dont 13 millions à charge de la Commission européenne via un fi nancement lié au 6ème programme-cadrede recherche communautaire.L'objectif principal de Co-Extra est de fournir les outils nécessaires à l'implémentation de la coexistence et de latraçabilité en vue d'assurer la coexistence des fi lières utilisant des produits OGM, conventionnels ou dérivés del'agriculture biologique. Ce projet intégré complète deux autres programmes européens: SIGMEA qui porte principalementsur la coexistence au niveau de la production agricole et Transcontainer focalisé sur les méthodes debioconfi nement. %B LabInfo %V 3 %P 22 - 23 %8 0/0/2009 %G eng %N Novembre 2009 %1 2804 %& 22 %0 Government Document %D 2009 %T European project Co-Extra: GM and non-GM supply chains: their co-existence and traceability %A Didier Breyer %A Nancy Roosens %A Berben,G. %A Isabel Taverniers %A Marc Van den Bulcke %A Myriam Sneyers %K abstract %K co-existence %K Co-Extra %K coexistence %K European %K GM %K GMO %K Project %K traceability %X

No abstract

%B LabInfo %I xx %C Brussels %V 3 %P 22 - 23 %8 1/11/2009 %G eng %1 363 %& 22 %0 Journal Article %J Environ Biosafety Res %D 2009 %T Genetic modification through oligonucleotide-mediated mutagenesis. A GMO regulatory challenge? %A Didier Breyer %A Philippe Herman %A Brandenburger, Annick %A Gheysen, Godelieve %A Remaut, Erik %A Soumillion, Patrice %A Van Doorsselaere, Jan %A Custers, René %A Katia Pauwels %A Myriam Sneyers %A Reheul, Dirk %K Animals %K Animals, Genetically Modified %K European Union %K genetic engineering %K Government Regulation %K International Cooperation %K mutagenesis %K Plants, Genetically Modified %X

In the European Union, the definition of a GMO is technology-based. This means that a novel organism will be regulated under the GMO regulatory framework only if it has been developed with the use of defined techniques. This approach is now challenged with the emergence of new techniques. In this paper, we describe regulatory and safety issues associated with the use of oligonucleotide-mediated mutagenesis to develop novel organisms. We present scientific arguments for not having organisms developed through this technique fall within the scope of the EU regulation on GMOs. We conclude that any political decision on this issue should be taken on the basis of a broad reflection at EU level, while avoiding discrepancies at international level.

%B Environ Biosafety Res %V 8 %P 57-64 %8 2009 Apr-Jun %G eng %N 2 %1 http://www.ncbi.nlm.nih.gov/pubmed/19833073?dopt=Abstract %R 10.1051/ebr/2009007 %0 Government Document %D 2009 %T Should novel organisms developed using oligonucleotide-mediated mutagenesis be excluded from the EU Regulation %A Didier Breyer %A Philippe Herman %A Brandenburger,A. %A Gheysen,G. %A Remaut,E. %A Soumillion,P. %A J. Van Doorsselaere %A Custers,R. %A Katia Pauwels %A Myriam Sneyers %A Reheul,D. %K EU %K mutagenesis %K New techniques %K Paper %K regulation %K Regulatory %K SAFETY %K SBB %K Technique %K use %K website %X

This paper discusses regulatory and safety issues associated with the use of oligonucleotide-mediated mutagenesis and provides scientific arguments for not having organisms developed through this technique fall within the scope of the EU regulation of GMOs.

%B ISB news report %I ISBN %C Brussels %V November 2009 %P 2 - 12 %8 0/0/2009 %G eng %1 38519 %& 2 %0 Generic %D 2009 %T Towards an integrated Real-Time Q-PCR platform for GMO detection at low level presence %A A. Lievens %A Amaya Leunda %A Piednoir,E. %A Myriam Sneyers %A Marc Van den Bulcke %K an %K at %K Co-Extra %K Congresses %K detection %K GMO %K GMO detection %K International %K LEVEL %K low level %K qPCR %B Co-extra International Congress %I NA %C NA %8 3/6/2009 %G eng %N Co-extra International Congress %1 376 %2 03/06/2009 %0 Generic %D 2008 %T General presentation of the NRL-GMO and activities since 01/07/2007 %A Myriam Sneyers %K Activity %K Communication %K de %K general %K PRESENTATION %B Groupe de communication NRL %I NA %C NA %8 30/10/2008 %G eng %N NRL %1 387 %2 30/10/2008 %0 Government Document %D 2007 %T Animal cell cultures: Risk Assessment and biosafety recommendations %A Katia Pauwels %A Bernadette Van Vaerenbergh %A Chuong Dai Do Thi %A Berghmans,L. %A Geneviève Waeterloos %A Van Bockstaele,D. %A Dorsch-Hasler,K. %A Myriam Sneyers %K Activity %K an %K Animal %K AS %K assessment %K at %K biosafety %K Case %K cell culture %K cells %K compliance %K containment %K environment %K EVALUATION %K general %K genetic modification %K hazard %K health %K Human %K human health %K IS %K LEVEL %K measure %K measures %K ON %K ORIGIN %K pathogen %K pathogenic %K recommendation %K Recommendations %K Reduction %K Research %K result %K risk %K Risk Assessment %K risks %K SBB %K Type %K use %K work %X During the last three decades, animal cell culturing hasbeen essential for biomedical research and biotechnologicalactivities in general. Along with this increasing importance,biosafety concerns have pointed to the risks of manipulatinganimal cell cultures for human health and the environment. Amaximal reduction of these risks necessitates a thorough riskassessment of the cell cultures used. It involves an evaluationof both the intrinsic properties of the cell culture, includingsubsequent properties acquired as a result of genetic modification,and the possibility that the cell culture may inadvertentlyor deliberately become contaminated with pathogens.The latter is a major hazard associated with the manipulationof animal cell cultures, as adventitious agents may be pathogenicand have a better capacity to survive in unfavorableconditions. Consequently, most of the containment measuresprimarily aim at protecting cells from adventitious contamination.Therefore, a comprehensive evaluation of the risks encounteredduring the handling of cell cultures should includeconsiderations regarding the type of manipulation as well. Asa rule, cell cultures known to harbor an infectious etiologicagent should be manipulated in compliance with containmentmeasures recommended for the etiologic agent. With the exceptionof very well-characterized cell cultures for which theuse of a type II biosafety cabinet depends on the origin of thecells, work with cell cultures from human or primate originshould generally and minimally be performed under containmentlevel 2 using a type II biosafety cabinet. In every case,containment measures should minimize adventitious contaminationof the cell cultures and offer a maximal protection ofhuman health and the environment. %B Appl.Biosaf. %V 12 %P 26 - 38 %8 0/0/2007 %G eng %N 1 %1 1899 %& 26 %0 Journal Article %J Biotechnol J %D 2007 %T Bringing scientists to the people--the Co-Extra website. %A Didier Breyer %A Pierre Daubresse %A Myriam Sneyers %K Biotechnology %K Communication %K Europe %K Information Dissemination %K Internet %K Public Opinion %K Public Relations %K Science %X

Disseminating and facilitating access to science-based information is a necessity to enable the public to make informed decisions about appropriate uses of biotechnology products. It is also one of the major objectives of Co-Extra, a European-funded project addressing co-existence of genetically modified organisms and non-genetically modified organisms in Europe and their traceability. To this end, a dynamic and interactive website has been developed as the core element of the Co-Extra external communication strategy. This website has been designed to make it attractive and accessible to a large audience in a very simple and practical manner, building on practical experiences gained in the development of other websites related to biotechnology and genetically modified organisms. The website delivers popularized information for the general public as well as scientific data meant primarily for the more expert readers. It also provides for various permanent tools allowing multidirectional interaction with its visitors. Content is displayed using a web-based platform, based on a sophisticated Content Management System. First results indicate a high level of interest from the general public and from experts, showing that the content of this website can contribute by communicating science-based information to improve awareness and understanding of biotechnology.

%B Biotechnol J %V 2 %P 1081-5 %8 2007 Sep %G eng %N 9 %1 http://www.ncbi.nlm.nih.gov/pubmed/17703490?dopt=Abstract %R 10.1002/biot.200700115 %0 Book %B Towards a safer food supply in Europe %D 2007 %T Challenges for future research in GMO detection %A Berben,G. %A F. Debode %A M. De Loose %A E. Janssen %A N. Papazova %A Myriam Sneyers %A I. Taverniers %A Amaya Leunda %A Adinda De Schrijver %A Marc Van den Bulcke %E C.Van Peteghem %K event-specific identification %K fingerprinting %K GMO characterization %K Method validation %K qualitative PCR %K QUALITY ASSURANCE %K Quantitative real-time PCR %K SCREENING %X This article reviews several research challenges for GMO detection as some pending questions still exist and need more research efforts to be solved. The question of how to apply validation in a modular scheme is handled. It is followed by the problem of how to manage the detection of an always increasing number of new events and the fact that in such a context screening will probably be more and more important. The issue of detection of unauthorized GMOs with special attention to unknown GMOs is considered. Some technical limitations in result expression with respect to botanical impurities or stacked events are also addressed. Finally the establishment of plasmid reference calibrants as alternative to the current plant-derived certified reference materials, their distribution and utilisation are discussed. %B Towards a safer food supply in Europe %I Belgian Science Policy %C Brussels %P 95 - 112 %@ 978-90-8756-032-4 %G eng %1 38512 %& 95 %0 Journal Article %J Eur. Food Res. Technol. %D 2007 %T Detection of genetically modified plant products by protein strip testing: An evaluation of real-life samples %A Marc Van den Bulcke %A Adinda De Schrijver %A De Bernardi,D. %A Y. Devos %A G.E. Mbongolo-Mbella %A Amaya Leunda %A W. Moens %A Myriam Sneyers %X The determination of the presence of genetically modified plant material by the detection of expressed genetically engineered proteins using lateral flow protein strip tests has been evaluated in different matrices. The presence of five major genetically engineered proteins (CP4-EPSPS, CryIAb, Cry9C, PAT/pat and PAT/bar protein) was detected at low levels in seeds, seed/leaf powder and leaf tissue from genetically modified soy, maize or oilseed rape. A comparison between "protein strip test" (PST) and "polymerase chain reaction" (PCR) analysis of genetically modified food/feed samples demonstrates complementarities of both techniques. -® Springer-Verlag 2007 %B Eur. Food Res. Technol. %V 225 %P 49 - 57 %G eng %N 1 %1 2797 %& 49 %R http://dx.doi.org/ %0 Book %B Towards a safer food supply in Europe %D 2007 %T Regulatory/legal framework of GMO detection2801 %A Marc Van den Bulcke %A Myriam Sneyers %E Carlos Van Peteghem %K a %K AS %K Commercialization %K Control %K detection %K detection method %K EU %K Europe %K feed %K food %K Food Supply %K GMO %K GMO detection %K GMOs %K IS %K labeling %K method %K methods %K plant %K production %K PRODUCTS %K Quantification %K regulation %K relative %K SBB %K threshold %K traceability %K treshold %K website %X In the EU, the production and commercialization of GMOs and GMO-containing or -derived food and feed products are regulated by the 'Food and Feed' Regulation (EC)No 1829/2003 and the 'Labeling and Traceability' Regulation (EC) No 1830/2003.Labelling is mandatory above a 0.9% threshold GMO percentage, relative peringredient (and translated as plant taxa for analytical purposes). Analytical methods fordetection and accurate quantification of GMO contents in derived food and feedproducts, require robust detection methods and adequate reference materials asidentifier and quantifier controls. %B Towards a safer food supply in Europe %7 335 %I Belgian Science Policy %C Brussels %P 335 %8 0/0/2007 %@ 978-90-8756-032-4 %G eng %1 39014 %& 81 %0 Report %D 2006 %T Biosafety recommendations for the contained use of Mycobacterium tuberculosis complex isolates in industrialized countries %A Philippe Herman %A M. Fauville %A Didier Breyer %A Bernadette Van Vaerenbergh %A Katia Pauwels %A Chuong Dai Do Thi %A Myriam Sneyers %A Wanlin,M. %A Snacken,R. %A William Moens %K a %K Activity %K Aerosols %K Airborne %K an %K analysi %K analysis %K AS %K Belgium %K biosafety %K BSL-3 %K classification %K Clinical %K containment %K Countries %K culture %K developed countries %K Diagnosis %K disease %K Diseases %K Dna %K Group %K Human %K identification %K incidence %K INFECTION %K Infectious %K Infectious diseases %K International %K IS %K IT %K Laboratories %K Less %K LEVEL %K M %K M tuberculosis %K Mycobacterium %K Mycobacterium tuberculosis %K ON %K pathogen %K People %K Practice %K PRACTICES %K recommendation %K Recommendations %K Research %K risk %K Rna %K SAFETY %K SBB %K Secondary %K specific %K Test %K tests %K time %K Times %K Transmission %K Tuberculosis %K use %K website %K work %X Staff working in microbiological diagnostic and research laboratories is likely to be exposed to infection risk with pathogens. Among human infectious diseases, tuberculosis is one of the most severe, killing 2 millions people worldwide every year. %I Scientific Institute of Public Health %C Brussels %V D/2006/2505/22 %P 17 %8 0/0/2006 %G eng %1 38754 %& 2 %0 Government Document %D 2004 %T Biosafety risk assessment of the Severe Acute Respiratory Syndrome (SARS) coronavirus and containment measures for the diagnostic and research laboratories %A Philippe Herman %A Verlinden,Y. %A Didier Breyer %A Van Cleemput,E. %A Bernard Brochier %A Myriam Sneyers %A Snacken,R. %A Hermans,P. %A Pierre Kerkhofs %A Liesnard,C. %A Rombaut,B. %A Marc Van Ranst %A van der Groen,G. %A Goubau,P. %A William Moens %K Activity %K Africa %K ALL %K an %K AS %K assessment %K at %K Belgium %K biosafety %K Case %K containment %K Control %K Coronavirus %K Countries %K disease %K environment %K Europe %K Guidelines %K health %K Human %K INFECTION %K International %K investigation %K IS %K Laboratories %K LEVEL %K levels %K measure %K measures %K ON %K Order %K organization %K POPULATION %K Practice %K PRACTICES %K production %K recommendation %K Recommendations %K Research %K Respiratory %K response %K risk %K Risk Assessment %K SAFETY %K SARS %K SBB %K Spread %K use %K VIRUS %K WHO %K work %K world %K World Health Organization %X At the end of 2002, an outbreak of a new viral respiratory illness, called SARS (Severe Acute Respiratory Syndrome virus) occurred in China. The disease spread over Asia, North America, Europe and Africa. In response to the SARS outbreak, the World Health Organization (WHO) coordinated an international collaboration that included clinical, epidemiologic and laboratory investigations, and initiated efforts to control the spread of SARS. As in other countries it has been decided to establish biosafety guidelines and recommendations in Belgium with particular emphasis on handling clinical specimens associated with SARS for research, production and clinical laboratories. Taking into account that there is so far no SARS case reported in Belgium as well as in other countries in the world, and based on a scientific risk assessment related to the contained use of biological agents, the SARS-CoV was classified as a Risk Group 3 agent. In relation to the reported biosafety assessment, the SARS-CoV should be handled in appropriate biosafety containment levels in order to avoid laboratory acquired infections and spread of the disease in the human population and the environment. Therefore, diagnostic activities with inactivated clinical specimens associated with SARS cases and specimens originating from countries where SARS is documented but not associated with SARS cases, should be performed under Biosafety Level 2 (BSL-2) conditions. Diagnostic activities involving non-inactivated clinical specimens associated with SARS should be carried out under BSL-2 containment with BSL-3 safety equipment and work practices. Culture of SARS-CoV and all research activities involving SARS-CoV require a BSL-3 containment %B Appl.Biosaf. %V 9 %P 128 - 142 %8 0/0/2004 %G eng %N 3 %1 360 %& 128 %0 Report %D 2003 %T Report: "Demonstrating the quality of implementing Polio laboratory containment requirements" %A Myriam Sneyers %K accuracy %K Activity %K aims %K Belgium %K containment %K Help %K i %K Infectious %K Inventory %K Laboratories %K national %K Poliovirus %K Quality %K report %K SBB %K survey %K website %K WHO %X This document aims to help WHO to assess the quality of phase I containment activities inBelgium, thus to document the thoroughness and accuracy of conducting the LaboratorySurvey and establishing the National Inventory of laboratories that wish to retain wildpoliovirus infectious materials. %I Scientific Institute of Public Health %C Brussels %P 22 %8 0/0/2003 %G eng %1 38878 %& 1 %0 Journal Article %J Hum.Gene Ther. %D 2001 %T Gene therapy clinical trials in Belgium %A Myriam Sneyers %A Dumon,J.C. %A Bernadette Van Vaerenbergh %A William Moens %K Belgium %K biosafety %K Biotechnology %K Brussels %K clinical trial %K Clinical trials %K Database %K European %K European Union %K gene %K gene therapy %K health %K INFORMATION %K Institute %K Paper %K public %K public health %K Public-health %K Regulatory %K SBB %K Service %K Therapy %X The present paper briefly describes the missing information about gene therapy clinical trials authorized in Belgium in relation with the regulatory framework. It also proposes a basic database format, complying with legal confidentiality rules. We then discuss transparency in the gene therapy field within the European Union. %B Hum.Gene Ther. %V 12 %P 1361 - 1365 %8 0/0/2001 %G eng %N 10 %1 2819 %& 1361 %R http://dx.doi.org/ %0 Report %D 2000 %T Rapport: Premier décès rapporté de thérapie génique %A Dumon,J.C. %A Myriam Sneyers %A William Moens %K de %K gene therapy %K rapport %K report %K SBB %K Therapy %K website %I WIV-ISP %C Bruxelles %P 20 %8 0/0/2000 %G eng %1 38702 %& 1 %0 Report %D 2000 %T Report: First gene therapy related death %A Dumon,J.C. %A Myriam Sneyers %A William Moens %K gene %K gene therapy %K report %K SBB %K Therapy %K website %I WIV-ISP %C Brussels %P 20 %8 0/0/2000 %G eng %1 38701 %& 1 %0 Report %D 2000 %T Verslag: Eerste gerapporteerde sterfgeval ten gevolge van gentherapie %A Dumon,J.C. %A Myriam Sneyers %A William Moens %K gene therapy %K report %K SBB %K Therapy %K website %I WIV-ISP %C Brussel %P 21 %8 0/0/2000 %G eng %1 38703 %& 1 %0 Government Document %D 1997 %T Manipulation d'organismes pathogènes ou génétiquement modifiés dans les hôpitaux %A J-M Collard %A Didier Breyer %A Myriam Sneyers %A Bernadette Van Vaerenbergh %A William Moens %K containment %K GMO %K hospital %K LE %K pathogen %K pathogène %K SBB %X Not available %B Het Belgisch Ziekenhuis %V 4 %P 55 - 62 %8 0/0/1997 %G eng %1 2753 %& 55 %0 Patent %D 0 %T Transgenic plant event detection %A Marc Van den Bulcke %A A. Lievens %A Amaya Leunda %A G.E. Mbongolo-Mbella %A Piednoir,E. %A Myriam Sneyers %K detection %K Development %K feed %K food %K plant %K Plants %K PRODUCTS %K Transgenic %7 08708376.2 %8 2007 %N 29/01/2008 %& WO2008EP51059